<\/p>\n
Selgin<\/strong> or\u00e1lis selegiline<\/strong> (5 mg) tablet \u2014 a selective monoamin-oxid\u00e1z-B (MAO-B) g\u00e1tl\u00f3<\/strong> 2-es t\u00edpus\u00fa diabetes kezel\u00e9s\u00e9re haszn\u00e1lj\u00e1k Parkinson-k\u00f3r<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Selegiline is metabolised to L-amphetamine and L-methamphetamine<\/strong>, which can contribute to insomnia — take morning doses only. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Fontos:<\/strong> ker\u00fclje a legt\u00f6bb antidepressz\u00e1nssal (SSRI-k, SNRI-k, TCA-k), opioidokkal, mint p\u00e9ld\u00e1ul a pethidin \u00e9s a tramadol, valamint a dextrometorf\u00e1nnal val\u00f3 kombin\u00e1l\u00e1s\u00e1t \u2014 kock\u00e1zata a szerotonin szindr\u00f3ma<\/em>.<\/p>\n<\/div>\n \ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n Selgin is an oral tablet containing selegiline 5 mg<\/strong>. selegiline is a selective monoamin-oxid\u00e1z-B (MAO-B) g\u00e1tl\u00f3<\/strong> eredetileg Eldepryl \/ Jumex<\/strong>. Selgin is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n Selegiline was the first MAO-B inhibitor used in Parkinson disease, in clinical use since the 1980s. It can be used as N\u00e9ha mint<\/em> in early Parkinson disease (modest symptomatic benefit, may delay the need for levodopa by months) or as kieg\u00e9sz\u00edt\u0151 ter\u00e1pia<\/em> to levodopa to reduce “wearing-off” between doses. Its distinctive feature among MAO-B inhibitors is that it is metabolised to amphetamine derivatives, which contribute to a mild stimulant effect — useful for fatigue but a frequent cause of insomnia.<\/p>\n In the brain, dopamine is degraded mainly by monoamine oxidase type B (MAO-B). Selegiline irreversibly inactivates MAO-B at standard doses (5–10 mg\/day), so dopamine released from surviving neurones lingers longer in the synapse. The result: smoother symptom control and a longer benefit from each levodopa dose. Selegiline is also metabolised to L-amphetamine and L-methamphetamine, which independently contribute mild stimulant and dopaminergic effects. Above 10 mg\/day, selectivity for MAO-B is lost and MAO-A inhibition becomes clinically meaningful — tyramine restriction then becomes important.<\/p>\n A Parkinson-k\u00f3r kezel\u00e9s\u00e9ben haszn\u00e1lt h\u00e1rom MAO-B g\u00e1tl\u00f3 \u2014 szelegilin, raszagilin \u00e9s safinamid \u2014 k\u00f6z\u00f6s mechanizmus\u00fa, de jelent\u0151sen elt\u00e9rnek a metabolitjaik, adagol\u00e1suk \u00e9s klinikai pozicion\u00e1l\u00e1suk tekintet\u00e9ben:<\/p>\nMi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n
What Is Selgin?<\/h2>\n
How Does Selgin (selegiline) Work?<\/h2>\n
Az MAO-B g\u00e1tl\u00f3k \u00f6sszehasonl\u00edt\u00e1sa<\/h2>\n